{"id":"crushed-ticagrelor-morphine-naloxone","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (ticagrelor)"},{"rate":null,"effect":"Bradycardia (ticagrelor)"},{"rate":null,"effect":"Dyspnea (ticagrelor)"},{"rate":null,"effect":"Nausea/vomiting (morphine)"},{"rate":null,"effect":"Constipation (morphine)"},{"rate":null,"effect":"Dizziness (morphine)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor is a P2Y12 platelet receptor antagonist that prevents thrombotic events. Morphine is an opioid agonist providing analgesia and anxiolysis. Naloxone is an opioid antagonist included to mitigate morphine's respiratory depression and other opioid-related side effects while maintaining analgesic efficacy. This combination appears designed for acute coronary syndrome or post-acute cardiac care with pain management.","oneSentence":"This combination uses ticagrelor to inhibit platelet aggregation, morphine for pain relief and anxiolysis, and naloxone as an opioid antagonist to reduce morphine-related adverse effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:36:55.995Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with pain management"},{"name":"Post-acute cardiac event analgesia"}]},"trialDetails":[{"nctId":"NCT02939248","phase":"PHASE4","title":"Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2016-10","conditions":"Unstable Angina Pectoris","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brilique"],"phase":"marketed","status":"active","brandName":"Crushed ticagrelor, morphine,naloxone","genericName":"Crushed ticagrelor, morphine,naloxone","companyName":"Collegium Medicum w Bydgoszczy","companyId":"collegium-medicum-w-bydgoszczy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses ticagrelor to inhibit platelet aggregation, morphine for pain relief and anxiolysis, and naloxone as an opioid antagonist to reduce morphine-related adverse effects. Used for Acute coronary syndrome with pain management, Post-acute cardiac event analgesia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}